SCHEMBL2409347

SCHEMBL2409347

O=C(Cc1cccnc1)c1c(O)c2cccnc2n(-c2ccccc2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.47
PDE1B Q01064 1/20 0.47
PDE4A P27815 6/20 0.46
PDE7A Q13946 1/20 0.46
FEN1 P39748 1/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
ALOX12 P18054 1/20 0.45
REN P00797 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
PDE4B Q07343 5/20 0.42
PDE4C Q08493 5/20 0.42
PDE4D Q08499 5/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2409456 0.92 PDE1A (0.51) PDE1APDE1BPDE4AFEN1ALDH1A1
SCHEMBL2411216 0.91 PDE1A (0.46) PDE1APDE1BPDE4APDE7AFEN1
SCHEMBL2413828 0.86 PDE1A (0.49) PDE1APDE1BPDE4AFEN1ALDH1A1
SCHEMBL9046658 0.85 ALDH1A1 (0.63) KDM4EALDH1A1LMNAALOX12CNR1
SCHEMBL2408715 0.85 CNR2 (0.47) PDE1APDE1BPDE4AFEN1ALDH1A1
SCHEMBL2408445 0.84 PDE1A (0.47) PDE1APDE1BPDE4AFEN1ALDH1A1
SCHEMBL2411173 0.83 FEN1 (0.46) PDE1APDE1BPDE4APDE7AFEN1
SCHEMBL2414794 0.82 PTGDR2 (0.46) PDE1APDE1BPDE4AFEN1KDM4E
SCHEMBL2409205 0.82 FEN1 (0.43) PDE1APDE1BPDE4AFEN1REN
SCHEMBL2411916 0.82 USP14 (0.46) PDE1APDE1BPDE4AFEN1REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A PDE1A 28/4885PDE1B 24/4885PDE4A 3/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A PDE1A 30/4885PDE1B 23/4885PDE4A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.